Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 52.5 EUR 2.34%
Market Cap: 927.2m EUR
Have any thoughts about
Formycon AG?
Write Note

Formycon AG
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Formycon AG
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Formycon AG
XETRA:FYB
Accounts Receivables
€28.2m
CAGR 3-Years
54%
CAGR 5-Years
40%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Accounts Receivables
€2.2B
CAGR 3-Years
136%
CAGR 5-Years
158%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Accounts Receivables
€25.9m
CAGR 3-Years
-37%
CAGR 5-Years
5%
CAGR 10-Years
10%
CureVac NV
NASDAQ:CVAC
Accounts Receivables
€17.1m
CAGR 3-Years
112%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Accounts Receivables
€4.1m
CAGR 3-Years
47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Accounts Receivables
€170m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
0%
No Stocks Found

Formycon AG
Glance View

Market Cap
927m EUR
Industry
Biotechnology

Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

FYB Intrinsic Value
77.46 EUR
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Formycon AG's Accounts Receivables?
Accounts Receivables
28.2m EUR

Based on the financial report for Dec 31, 2023, Formycon AG's Accounts Receivables amounts to 28.2m EUR.

What is Formycon AG's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
40%

Over the last year, the Accounts Receivables growth was 82%. The average annual Accounts Receivables growth rates for Formycon AG have been 54% over the past three years , 40% over the past five years .

Back to Top